- Company
- Two pharmaceutical unions unite with each other
- by Jul 7, 2022 05:54am
- With the birth of the nation's largest pharmaceutical industry union, the number of unions affiliated with the Federation of Korean Trade Unions in the pharmaceutical industry has increased to two. This includes corporate unions that have withdrawn from the existing industrial unions, drawing keen attention to the background. The NPU was l
- Company
- First KRAS lung cancer drug Lumakras released next month
- by Jul 7, 2022 05:54am
- Non-small cell lung cancer patients with KRAS mutations are expected to be able to receive treatment with the targeted anticancer therapy ‘Lumakras (sotorasib)’ starting this August. Amgen announced it will actively increase diagnostic tests and pursue reimbursement listing for the drug to increase accessibility to the only KRAS-targeted thera
- Company
- Novonodisk labor union announces union struggle on 7th
- by Eo, Yun-Ho Jul 7, 2022 05:54am
- Novonodisk Pharmaceutical's labor union under the NPU will hold regular general meetings and fight for all members. Novonodisk labor union is currently fighting against ▲ wage negotiations broke down in 2021, ▲petition of the Ministry of Labor regarding wage arrears due to the change in the disadvantage of the sales department incentive sys
- Company
- Next-gen breast cancer drug, pneumococcal vaccine to come
- by Jul 6, 2022 05:47am
- New big drugs, including a pneumococcal vaccine, a macular degeneration treatment, and a breast cancer treatment, are expected to receive approval from the Ministry of Food and Drug Safety in the second half of this year. According to industry sources on the 6th, new drugs such as ▲Vaxneuvance (MSD) ▲Enhertu (Daiichi Sankyo) ▲Vabysmo (Roch
- Company
- BL’s COVID-19 treatment expands indication to pneumonia
- by Lee, Seok-Jun Jul 6, 2022 05:47am
- BL is aiming to adopt an indication expansion strategy and develop 'BLS-H01,’ its new drug for COVID-19 treatment for which a Phase II trial is underway, as a broad-spectrum treatment for pneumonia. According to BL on the 5th, BLS-H01 is an immunoregulatory treatment that contains a gamma PGA. A clinical trial is currently underway to ass
- Company
- 2nd generation EGFR TKI Vizimpro can be prescribed in Big 5
- by Eo, Yun-Ho Jul 6, 2022 05:47am
- Pfizer's second-generation EGFR TKI Vizimpro has settled in the Big 5 General Hospital. According to related industries, Pfizer's EGFR TKI Vizimpro recently passed all five major medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Asan Medical Center, and Sinchon Severance Hospit
- Company
- There are many complaints about the revaluation of generics
- by Chon, Seung-Hyun Jul 6, 2022 05:46am
- Pharmaceutical companies complain of unnecessary waste of money on products being sold without problems. Pharmaceutical companies are struggling ahead of the general drug price revaluation. There are many concerns that the biological equivalent test, which was conducted with the aim of maintaining drug prices, could lead to a reduction in dru
- Company
- Sanofi & MDsquare co-promote Digital Healthcare Business
- by Jul 5, 2022 05:58am
- Sanofi Korea Corporation announced on the 4th that it held a (MOU) signing ceremony with MDsquare to promote digital healthcare business on the 30th of last month. With this agreement, Sanofi provides chronic disease management and prevention information, and MDsquare develops premium health care programs to cooperate so that patients with
- Company
- RDK introduces monkeypox PCR test kits to Korea
- by Jul 5, 2022 05:58am
- On the 4th, Roche Diagnostics Korea announced that it had introduced PCR diagnostics kits for the detection of the monkeypox virus in Korea. The three kits that were introduced to Korea this time -▲ LightMix Modular Orthopox Virus, ▲ LightMix Modular Monkeypox Virus, and ▲ LightMix Modular Orthopox Virus typing1- were developed by Roch
- Company
- CKD voluntarily discontinues P3T on its COVID-19 therapy
- by Kim, Jin-Gu Jul 4, 2022 05:55am
- Chong Kun Dang issued a public notice on the 1st that it will discontinue the Phase III trial on its CKD-314 (Nafabeltan Inj.) it had been developing as a COVID-19 treatment. Chong Kun Dang explained, “We found it difficult to conduct a clinical trial to identify the patients’ rate of progression to severe disease due to the reduced inc
